biotech / news / / The Manila Times
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.
GHIT Fund is investing JPY 700 million in preclinical development of a novel antimalarial drug.
KEY POINTS
- A new trial in Kenya, Senegal, and India will seek WHO registration for fosravuconazole for eumycetoma.
- No mycetoma drug had been evaluated via randomized controlled trials before GHIT's Sudan trial.
- GHIT also funds three new antimalarial projects focusing on novel drug targets and mechanisms.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →